Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28

Canaccord Genuity has initiated coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Buy rating. The firm has set a price target of $28 for the company's stock.